ProjectTWIGHLIGHT Study – Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Basic data
Acronym:
TWIGHLIGHT Study
Title:
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Duration:
22/09/2015 to 31/12/2018
Abstract / short description:
The primary objective of this study is to determine the impact of antiplatelet monotherapy with ticagrelor alone versus DAPT with ticagrelor plus aspirin for 12 months in reducing clinically relevant bleeding among high-risk patients undergoing PCI who have completed a 3-month course of aspirin plus ticagrelor.
The secondary objective of this study is to determine the impact of antiplatelet monotherapy with ticagrelor alone versus DAPT with ticagrelor plus aspirin for 12 months in reducing major ischemic adverse events among high-risk patients undergoing PCI who have completed a 3-month course of aspirin plus ticagrelor.
The secondary objective of this study is to determine the impact of antiplatelet monotherapy with ticagrelor alone versus DAPT with ticagrelor plus aspirin for 12 months in reducing major ischemic adverse events among high-risk patients undergoing PCI who have completed a 3-month course of aspirin plus ticagrelor.
Keywords:
cardiovascular disease
Herzkreislauferkrankungen
Koronarstent
Thrombozytenaggregationshemmer
P2Y12-inhibitor
PTCA
Involved staff
Managers
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Internal Medicine Department III
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine